Evigrade
Critical

Co-trimoxazole × Methotrexate

Sulfonamide-trimethoprim combination×Antimetabolites, folic acid analogues

Mechanism

Co-trimoxazole contains trimethoprim, a dihydrofolate reductase inhibitor. Methotrexate blocks the same enzyme system. Co-administration intensifies the antifolate effect and suppresses haematopoiesis. Fatal pancytopenia and severe mucositis have been reported, even at low rheumatological methotrexate doses.

Symptoms

Stomatitis, mouth ulcers, nausea. Then – falling leukocyte and platelet counts: increased infection susceptibility and bleeding. Severe cases progress to fatal pancytopenia. Symptoms appear after 1–2 weeks of combined dosing.

Management

The combination is not recommended. For urinary tract infections in a patient on methotrexate, use nitrofurantoin or fosfomycin. For Pneumocystis infection where co-trimoxazole cannot be replaced, hold methotrexate for the antibiotic course and check full blood count every 3–5 days. Folic acid supplementation is mandatory.

Check the full regimen, not just this pair

Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.

Open checker

Sources

All interactions